pre-IPO PHARMA

COMPANY OVERVIEW

Triphase Accelerator is a private drug development company with a primary focus on oncology and operations in Toronto and San Diego. Triphase Accelerator is dedicated to advancing novel compounds through Phase 2 proof-of-concept clinical studies using a unique, science-based model that is faster and more cost-effective than traditional pharmaceutical and biotech industry drug development approaches. Triphase Accelerator was founded by the Ontario Institute for Cancer Research (OICR) and FACIT, in partnership with Toronto Innovation Acceleration Partners (TIAP) and MaRS.


LOCATION


THERAPEUTIC AREAS


WEBSITE

https://www.triphaseco.com


CAREER WEBSITE

None


SOCIAL MEDIA


INVESTORS


PRESS RELEASES


Feb 22, 2022

Triphase Accelerator Announces Positive Updated Phase 1 Data with TRPH-222 in Non-Hodgkin’s Lymphoma


Dec 7, 2020

Triphase Accelerator Announces Positive Interim Results of Phase 1 Trial of TRPH-222 in Patients with Relapsed/Refractory Non-Hodgkin Lymphoma


Apr 1, 2019

Triphase Accelerator Initiates Phase 1 Clinical Trial of TRPH-222 in B-cell Lymphoma


Jan 29, 2019

FACIT and Triphase Accelerator Announce New Partnership with Celgene for First-in-class WDR5 Leukemia Therapy


Jan 29, 2019

MaRS Innovation’s Triphase Accelerator Announces New Partnership with Celgene for First-in-class WDR5 Leukemia Therapy


For More Press Releases


Google Analytics Alternative